Validation of a Nomogram in the Prediction of Local Recurrence Risks after Conserving Surgery for Asian Women with Ductal Carcinoma in Situ of the Breast

被引:32
|
作者
Wang, F. [1 ]
Li, H. [2 ]
Tan, P. H. [3 ]
Chua, E. T. [1 ]
Yeo, R. M. C. [1 ]
Lim, F. L. W. T. [1 ]
Kim, S. W. [1 ]
Tan, D. Y. H. [1 ]
Wong, F. Y. [1 ]
机构
[1] Natl Canc Ctr Singapore, Div Radiat Oncol, Singapore 169610, Singapore
[2] Singapore Gen Hosp, Hlth Serv Res Unit, Singapore, Singapore
[3] Singapore Gen Hosp, Dept Pathol, Singapore, Singapore
关键词
Breast; DCIS; nomogram; prediction; recurrence; NUYS PROGNOSTIC INDEX; TUMOR RECURRENCES; CANCER; RADIOTHERAPY; OUTCOMES; POPULATION; SINGAPORE; TAMOXIFEN; SURVIVAL; UTILITY;
D O I
10.1016/j.clon.2014.08.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: At our centre, ductal carcinoma in situ (DCIS) was commonly treated with breast-conservation therapy (BCT). Local recurrence after BCT is a major concern. The aims of our study were to review the outcomes of DCIS treatment in our patients and to evaluate a nomogram from Memorial Sloan Kettering Cancer Centre (MSKCC) for predicting ipsilateral breast tumour recurrence (IBTR) in our Asian population. Materials and methods: Chart reviews of 716 patients with pure DCIS treated from 1992 to 2011 were carried out. Univariable Cox regression analyses were used to evaluate the effects of the 10 prognostic factors of the MSKCC nomogram on IBTR. We constructed a separate National Cancer Centre Singapore (NCCS) nomogram based on multivariable Cox regression via reduced model selection by applying the stopping rule of Akaike's information criterion to predict IBTR-free survival. The abilities of the NCCS nomogram and the MSKCC nomogram to predict IBTR of individual patients were evaluated with bootstrapping of 200 sets of resamples and the NCCS dataset, respectively. Harrell's c-index was calculated for each nomogram to evaluate the concordance between predicted and observed responses of individual subjects. Results: Study patients were followed up for a median of 70 months. Over 95% of patients received adjuvant radiotherapy. The 5 and 10 year actuarial IBTR-free survival rates for the cohort were 95.5 and 92.6%, respectively. In the multivariate analysis, independent prognostic factors for IBTR included use of adjuvant endocrine therapy, presence of comedonecrosis and younger age at diagnosis. These factors formed the basis of the NCCS nomogram, which had a similar c-index (NCCS: 0.696; MSKCC: 0.673) compared with the MSKCC nomogram. Conclusion: The MSKCC nomogram was validated in an Asian population. A simpler NCCS nomogram using a different combination of fewer prognostic factors may be sufficient for the prediction of IBTR in Asians, but requires external validation to compare for relative performance. (C) 2014 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:684 / 691
页数:8
相关论文
共 50 条
  • [1] Nomogram for Predicting the Risk of Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ
    Rudloff, Udo
    Jacks, Lindsay M.
    Goldberg, Jessica I.
    Wynveen, Christine A.
    Brogi, Edi
    Patil, Sujata
    Van Zee, Kimberly J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (23) : 3762 - 3769
  • [2] Margin width, and local recurrence after breast conserving surgery for ductal carcinoma in situ
    Ekatah, Gregory E.
    Turnbull, Arran K.
    Arthur, Laura M.
    Thomas, Jeremy
    Dodds, Christine
    Dixon, J. Michael
    EJSO, 2017, 43 (11): : 2029 - 2035
  • [3] Molecular Expression Assays Improve the Prediction of Local and Invasive Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ
    Hahn, Ezra
    Sutradhar, Rinku
    Paszat, Lawrence
    Nguyen, Lena
    Rodin, Danielle
    Nofech-Mozes, Sharon
    Trebinjac, Sabina
    Jerzak, Katarzyna J.
    Fong, Cindy
    Rakovitch, Eileen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (27) : 3196 - 3206
  • [4] A Nomogram Using Imaging Features to Predict Ipsilateral Breast Tumor Recurrence After Breast- Conserving Surgery for Ductal Carcinoma In Situ
    Choi, Bo Hwa
    Kang, Soohee
    Cho, Nariya
    Kim, Soo-Yeon
    KOREAN JOURNAL OF RADIOLOGY, 2024, 25 (10) : 876 - 886
  • [5] A Novel Nomogram for Predicting Prognosis and Tailoring Local Therapy Decision for Ductal Carcinoma In Situ after Breast Conserving Surgery
    Xu, Feifei
    Cao, Lu
    Xu, Cheng
    Cai, Gang
    Cai, Rong
    Qi, Weixiang
    Wang, Shubei
    Shen, Kunwei
    Chai, Weimin
    Chen, Jiayi
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (17)
  • [6] Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery
    Benson, John R.
    Wishart, Gordon C.
    LANCET ONCOLOGY, 2013, 14 (09) : E348 - E357
  • [7] Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
    Weinmann, Sheila
    Leo, Michael C.
    Francisco, Melanie
    Jenkins, Charisma L.
    Barry, Todd
    Leesman, Glen
    Linke, Steven P.
    Whitworth, Pat W.
    Patel, Rakesh
    Pellicane, James
    Warnberg, Fredrik
    Bremer, Troy
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 4054 - 4063
  • [8] Outcome and risk factors for local recurrence after breast conserving surgery in patients affected by ductal carcinoma in situ
    Tomasicchio, Giovanni
    Picciariello, Arcangelo
    Stucci, Luigia S.
    Panebianco, Annunziata
    Montanaro, Alda E.
    Cirilli, Alfredo
    Punzo, Clelia
    MINERVA SURGERY, 2022, 77 (06): : 536 - 541
  • [9] Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ
    Hassett, Michael J.
    Jiang, Wei
    Hughes, Melissa E.
    Edge, Stephen
    Javid, Sara H.
    Niland, Joyce C.
    Theriault, Richard
    Wong, Yu-Ning
    Schrag, Deborah
    Punglia, Rinaa S.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (04): : 387 - 394
  • [10] Molecular subtypes predict second breast events of ductal carcinoma in situ after breast-conserving surgery
    Yang, Yilan
    Zhao, Xu
    Wang, Xuanyi
    Jin, Kairui
    Luo, Jurui
    Yang, Zhaozhi
    Mei, Xin
    Ma, Jinli
    Shao, Zhimin
    Zhang, Zhen
    Chen, Xingxing
    Guo, Xiaomao
    Yu, Xiaoli
    CANCER MEDICINE, 2022, 11 (14): : 2755 - 2766